Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This scoping review found that microneedle patches loaded with exosomes, primarily derived from mesenchymal stem cells, show promising potential for delivering exosome therapies to treat non-cicatricial alopecia, suggesting new directions for enhancing hair follicle regeneration.

This study used human stem cell-derived skin organoids to model EV-A71 infection, revealing that various skin cell types are susceptible to the virus and identifying a potential drug target and replication inhibitor, suggesting its utility for studying skin infectious diseases and drug screening.

This source discusses drug repurposing, which seeks new therapeutic uses for existing drugs, emphasizing its benefits like faster development, reduced costs, and novel treatments for unmet medical needs. The chapter outlines current trends and future perspectives in drug discovery through repurposed drugs.

This review highlights significant advances in understanding and treating Alopecia Areata, emphasizing the effectiveness of JAK inhibitors like baricitinib, ritlecitinib, and deuruxolitinib for systemic treatment, while also noting ongoing research into new therapeutic approaches such as stem cell therapy and energy-assisted drug delivery.

This study reviewed recent literature and reported that although PRP products are recognized for benefits in dermatology, including wound care and hair growth, there remains a need for standardized protocols and consensus to enhance their acceptance in cosmetic dermatology.

This case study describes a 45-year-old man who developed post-finasteride syndrome with various symptoms after stopping Finasteride, highlighting the condition's rarity and poorly understood pathophysiology.

This review discusses the prevalence, pathogenesis, and treatments of androgenic alopecia but reports no new research findings; the authors emphasize the need for further exploration of novel treatment options.

This review concludes that low-level laser therapy is the most supported physical treatment for androgenetic alopecia, but other therapies like nonablative laser treatments and combinations including PEMF may also be promising.

Low-dose oral minoxidil is effective and generally safe for treating hair loss in women.

In this case report, off-label onabotulinumtoxin-A was successfully used to treat trichodynia, a painful scalp sensation associated with hair loss, in a patient unresponsive to conventional therapies.

This study found that the antiviral drug daclatasvir significantly improved fibrosis and quality of life in a mouse model of recessive dystrophic epidermolysis bullosa, suggesting potential for treating this and other fibrotic diseases.

This review examines the off-label use of low-dose oral minoxidil for treating alopecia, comparing it to topical minoxidil and discussing potential risks, benefits, and side effects, as well as nursing considerations for patient care.

In this case study, a patient with refractory oral lichen planus experienced marked improvement within one month of daily treatment with baricitinib, contributing to the evidence supporting the use of JAK inhibitors for lichen planus.

This study outlines treatment strategies for autoimmune alopecia areata, detailing that while mild cases may resolve on their own, severe cases often require intervention, with new JAK inhibitors like baricitinib and ritlecitinib emerging as promising treatments for those not responding to traditional therapies.

This study developed a method to measure local steroid hormone concentrations in hair, providing new insights into hormone dynamics associated with androgenetic alopecia.

This review discusses the potential of microneedling as a treatment for hair loss, suggesting it may stimulate hair growth through controlled skin trauma and growth factor release, but notes clinical data are limited and lacks standardized procedures.

This study found that nano-sized molybdenum accelerated hair growth and enhanced the effectiveness of minoxidil in a mouse model by reducing oxidative stress-related molecules.

This study found that the JAK3/TEC kinase inhibitor ritlecitinib was effective and well tolerated in patients aged 12 and older with alopecia areata, providing a potential systemic treatment option for this condition, especially in cases of significant psychosocial impact.

This study observed that most pediatric dermatologists prefer class 1 and 2 topical corticosteroids as first-line treatments for pediatric alopecia areata, with increasing use of JAK inhibitors as second-line therapy.

This systematic review concluded that mesotherapy shows potential for improving hair growth outcomes, yet lacks standardized regimens and requires further large-scale trials to establish its efficacy and safe use.

This article provides an overview of current treatments and alternative formulations for androgenic alopecia but reports no new clinical results.

In this study, the researchers identified that perturbing both AKT1 and MDM2 significantly reduces epithelial-mesenchymal transition in melanoma, proposing Cialis and Finasteride as potential therapeutic candidates with favorable properties for managing aggressive melanoma.

This source reports that clinical trials found oral baricitinib significantly improved hair regrowth in patients with severe alopecia areata, with 38.8% achieving at least 80% scalp hair coverage after 36 weeks on a 4-mg dose, compared to 6.2% with placebo in trial 1.

This article reviews drug repurposing as a strategy to overcome challenges in drug discovery, emphasizing AI and machine learning's role, but presents no new clinical results.

This chapter reviews various synthetic methods for creating pharmacologically active diazines, particularly focusing on pyrimidines, and discusses their potential in clinical applications. It also examines novel synthetic strategies that improve the drug-like qualities and safety profiles of these compounds.

This review explores the causes and diagnostic methods for androgenetic alopecia but reports no new clinical results, underlining the importance of developing new treatments.

Puradrop Extra Strength Gummies claim to support weight loss and boost energy using natural ingredients.

This piece describes the EndoPump Male Enhancement supplement, which claims to enhance erections and libido, but notes that there is insufficient medical evidence supporting the efficacy of its ingredients for sexual health.

This report highlights Amvuttra's approval for hATTR amyloidosis as a more convenient RNAi therapy, and Olumiant's attention as the first systemic drug for hair loss among recent developments.

This source notes that Olumiant (baricitinib), a rheumatoid arthritis drug by Eli Lilly and Company, has been approved as the first systemic treatment for severe alopecia areata.